Peter George joins Board of Ergomed as Non-Executive Director

He is currently Chief Executive of Clinigen

Peter George has joined the Board of Ergomed as Non-Executive Director.

George has more than 20 years’ experience in the pharmaceutical services industry and is currently Chief Executive of Clinigen, the global speciality pharmaceuticals and pharmaceutical services business. Prior to Clinigen, he was CEO at Penn Pharma, having led a £67m management company buyout in 2007.

Before this, George was Executive VP at Wolters Kluwer Health with responsibility for Europe and Asia Pacific regions. He has also held roles as Chief Operating Officer of Unilabs Clinical Trials International; Head of Clinical Pathology NHS and Director of PharmaPatents Global.

You may also like

Regulatory

Ergomed subsidiary PrimeVigilance enters US market and opens office in Boston, USA

US base gives PrimeVigilance the presence needed to support its current North American clients
Regulatory

Tivdak receives US FDA approval for treating recurrent cervical cancer

The full approval of tisotumab vedotin will offer a treatment for patients with metastatic or recurrent cervical cancer exhibiting disease progression on or after chemotherapy
Manufacturing

US court lifts modified consent decree on Xellia’s Cleveland facility

The Modified Consent Decree imposed on Xellia's Cleveland facility in 2016 has been vacated, receiving a VAI
Regulatory

Compact process thermostat for efficient temperature control in the lab

The Petite Fleur allows for laboratory reactor temperature control between -40 °C to +200 °C with a 480W refrigeration capacity
Regulatory

Broughton receives flexible scope ISO 17025 accreditation

New certification allows accreditation without prior approval
Regulatory

Overcoming CMC challenges in cell and gene therapy: part II

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Regulatory

Overcoming CMC challenges in cell and gene therapy: part I

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Subscribe now